China, India and the US will have the world’s largest populations of adults living with overweight and obesity by 2050, ...

A Central Illinois cardiologist breaks down the potential benefits of GLP-1 medications on heart health. It was one of the ...

Are GLP-1 therapies truly safe for long-term cardiovascular health? Dr Pandey unpacks key gaps in current research, ...

If obesity is seen not just as a personal struggle but a disease of public health concern, we can look for systemic solutions ...

How should you guide patients on GLP-1 therapy who are planning pregnancy? Dr Almandoz breaks down when to stop treatment, ...

The news has been littered with stories these days about people losing weight using GLP-1 weight loss drugs like Ozempic. Now ...

Insurer cites "significantly higher medical utilization with an expensive health care system, along with skyrocketing ...

Gut health brand Supergut has secured new capital from Full Frame Growth Partners, and brought in former CEO of Vital Proteins as CEO.

Blue Cross Blue Shield of Michigan reported a hefty $1.03 billion loss in 2024 as rising costs in the sector batter the health insurer's bottom line in “unsustainable” market conditions.

Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with ...

Anti-obesity GLP-1 medications aren't as effective as bariatric surgery for weight loss and improving obesity-related conditions ...

As consumers who use GLP-1 drugs seek lean, protein-rich foods, the demand for ground turkey has been increasing.